Epithelial-mesenchymal transition in prostate cancer: an overview

Micaela Montanari(University of Naples Federico II), Gaetano Facchini(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli)

Oncotarget

February 25, 2017

10.18632/oncotarget.15686

Cited by 177

Related Papers

Assessment of Total, PTEN–, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

|Clinical Genitourinary Cancer|2021|23

Epigenetic Silencing of <i>THY1</i> Tracks the Acquisition of the Notch1–EGFR Signaling in a Xenograft Model of CD44+/CD24low/CD90+ Myoepithelial Cells

|Molecular Cancer Research|2018|7

Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling

|Biomedicines|2021|2

Figure S6 from Epigenetic Silencing of <i>THY1</i> Tracks the Acquisition of the Notch1–EGFR Signaling in a Xenograft Model of CD44<sup>+</sup>/CD24<sup>low</sup>/CD90<sup>+</sup> Myoepithelial Cells

|Unknown|2023|0

Figure S3 from Epigenetic Silencing of <i>THY1</i> Tracks the Acquisition of the Notch1–EGFR Signaling in a Xenograft Model of CD44<sup>+</sup>/CD24<sup>low</sup>/CD90<sup>+</sup> Myoepithelial Cells

|Unknown|2023|0